TG Therapeutics at Cantor conference: briumvi gains momentum

TG Therapeutics said BRIUMVI IV is on track to exit 2024 at a $1 billion annualized sales run rate, while management characterized Street estimates of $1.2 billion for 2027 sales and roughly $2 billion IV peak sales as conservative. The company expects Roche's migration of OCREVUS patients from IV to subcutaneous and at-home administration to create an opening for BRIUMVI in infusion centers, supported by its 20%-25% price discount to OCREVUS and a nationwide DTC campaign rollout in 2H 2026. Phase III data for subcutaneous BRIUMVI are expected in late 2024 or early 2025, with management arguing its quarterly dosing and potential sales opportunity of more than double the IV franchise are underappreciated. Key risks remain commercial execution, future biosimilar and pricing pressure, and uncertainty around development and launch timelines.

Analysis

The investable issue is not the management upside narrative but whether TGTX can translate promotional spending and competitor disruption into durable net new starts without sacrificing net price. A nationwide patient campaign can lift demand over the next 1-3 quarters, but it also raises SG&A ahead of proof of incremental prescriptions; monitor quarterly revenue per patient, gross-to-net deductions and commercial expense as a percentage of sales. Management’s refusal to disclose current dynamic share makes the claimed competitive opening non-verifiable, so share gains—not exit-rate rhetoric—should drive conviction.

The key medium-term valuation catalyst is the subcutaneous formulation, but the market is likely to capitalize only a fraction of management’s peak-sales assertions until Phase III safety, injection-site tolerability, dosing durability and regulatory path are clear. If successful, subQ may cannibalize TGTX’s own IV franchise before expanding the addressable market, creating a mix shift with uncertain payer economics rather than a simple revenue add. Roche’s migration strategy could also prove a warning: convenience may matter more than infusion-center incentives, limiting the durability of an IV-share thesis.

Contrarian risk is that a successful BTK launch from NVS changes treatment sequencing rather than merely adding an option. Even modest oral adoption could pressure CD20 new-start share if physicians reserve B-cell depletion for later lines, while payer step edits can magnify that effect. The longer-dated patent narrative should receive little incremental multiple credit until independent IP review clarifies whether process and glycosylation claims withstand biosimilar challenge; management characterization alone is not diligence.

Key Decisions for Investors

• Maintain TGTX as a catalyst watch rather than add on conference-driven strength; initiate only after the next earnings report shows net product sales and patient starts above consensus while SG&A growth remains below revenue growth. Thesis fails on a guidance cut, material gross-to-net deterioration, or evidence that DTC spend is not converting into starts.
• For a 6-12 month event position, use a defined-risk TGTX call spread dated beyond the expected Phase III/regulatory decision window rather than outright stock; size small because binary clinical and approval risk can overwhelm commercial momentum. Add only if trial design, primary endpoint and filing timing are independently confirmed.
• Pair a modest long TGTX versus short XBI only if TGTX demonstrates two consecutive quarters of measurable share capture; this isolates company execution from biotech-beta volatility. Exit the pair if revenue growth decelerates despite rising commercial investment.
• Monitor NVS BTK data release and subsequent payer/formulary positioning as a read-through risk to TGTX. A clean efficacy/safety profile with favorable sequencing language would warrant reducing TGTX exposure before the market revises CD20 penetration assumptions.